Immunic appoints Maria Törnsén to Board of Directors; Jan Van den Bossche resigns

IMMUNIC, INC.

Appointed Maria Törnsén as Class III director, effective July 5, 2022, term until 2023 annual meeting.
Granted option to purchase 30,000 shares: 10,000 vesting monthly over 1 year, 20,000 over 3 years.
Jan Van den Bossche resigned from Board, effective July 5, 2022; no disagreement with company.
Törnsén brings 20 years commercial experience; current CCO at Passage Bio, previous roles at Sarepta, Sanofi, Shire.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Monika Maria Törnsén

Director

IMUX · IMMUNIC, INC.

Effective: 2022-07-05
Filed: July 8, 2022, 7:59 PM ET

On July 5, 2022, Immunic, Inc. (the “Company”) announced the appointment of Monika Maria Törnsén as a member of the Board of Directors (the “Board”) of the Company, effective as of July 5, 2022.

Departed

Jan Van den Bossche

Director

IMUX · IMMUNIC, INC.

Effective: 2022-07-05
Filed: July 8, 2022, 7:59 PM ET

The Company also announced that current Class III director, Jan Van den Bossche, will be resigning from the Board. The Board accepted Mr. Van den Bossche’s resignation effective July 5, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Monika Maria Törnsén was appointed as Director at IMMUNIC, INC..

Action: appointed
Role: Director

Exact text from the filing

On July 5, 2022, Immunic, Inc. (the “Company”) announced the appointment of Monika Maria Törnsén as a member of the Board of Directors (the “Board”) of the Company, effective as of July 5, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jan Van den Bossche resigned as Director at IMMUNIC, INC..

Action: resigned
Role: Director

Exact text from the filing

The Company also announced that current Class III director, Jan Van den Bossche, will be resigning from the Board. The Board accepted Mr. Van den Bossche’s resignation effective July 5, 2022.

View on SEC.gov

IMMUNIC, INC. filing history →

Source: SEC EDGAR

accession 0001193805-22-001069

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.